AI-powered QP-Prostate improves radiology workflow and prostate cancer detection
Prostate cancer is the second most prevalent cancer in men globally. Recent advancements in MRI technology have substantially improved the ability to detect and characterise prostate tumours. The Prostate Imaging-Reporting and Data System version 2.1 (PI-RADS v2.1) has been critical in improving the detection, localisation, characterisation, and risk stratification of lesions in untreated prostate glands, thereby facilitating more effective communication between clinicians and radiologists.
With MRI scans becoming the standard of care for prostate cancer and increasing populations at higher risk, many radiology departments face challenges in managing the influx of advanced medical imaging. Integrating AI-based medical devices into radiology has been optimised the interpretation of medical images and their incorporation with PACS. QP-Prostate from Quibim is an AI-driven tool designed to boost the accuracy, efficiency and consistency of prostate MRI examinations. The solution automates post-processing tasks, provides precise measurements, and expedites segmentation and reporting while enabling the management and annotation of regions of interest in the entire gland and suspicious areas. These features are accessible on DICOM workstations or within PACS.
One of the most significant advantages of QP-Prostate is its application of AI in lesion detection. This addresses the common challenge of variability in radiologists’ interpretations, says Quibim. “AI is a standardised, objective tool that diminishes disparities caused by differences in expertise and experience among radiologists. Consequently, it promotes more consistent clinically significant prostate cancer detection, ensuring better patient outcomes,” the company states.
We invite you to Quibim’s talk ‘QP-Prostate: unveiling a paradigm shift in prostate cancer management’, which takes place on Thursday, February 29, at 16.35 in the AI Theatre.
Visit Quibim at ECR on stand AI-42.
This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine. Visit our dedicated ECR conference page to find out more.